Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

52.200
+3.6007.41%
Volume:60.11M
Turnover:3.06B
Market Cap:216.37B
PE:38.54
High:52.450
Open:48.600
Low:48.120
Close:48.600
52wk High:52.450
52wk Low:28.480
Shares:4.15B
HK Float Shares:4.15B
Volume Ratio:1.25
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.355
ROE:11.64%
ROA:6.88%
PB:3.92
PE(LYR):38.54
PS:8.51

Loading ...

WuXi Biologics (Cayman) (SEHK:2269) Shares Climbed, So What Is Driving Attention Now?

Simply Wall St.
·
6 hours ago

WuXi XDC Grants 342,300 Restricted Shares to Employees Under 2024 Share Scheme

Reuters
·
Yesterday

WuXi Biologics Reports Strong Profitable Growth in H1 2026

THOMSON REUTERS
·
Yesterday

WuXi Biologics H1 Net Profit up on Margin Expansion

Reuters
·
Yesterday

Wuxi Bio's Interim Results Exceed Expectations and Break Broker Targets, with Accelerated Manufacturing Growth Reinforcing Long-Term Investment Thesis

Stock News
·
Yesterday

WuXi Bio Posts Robust H1 2026: Revenue Hits RMB 11.79 Billion, Adjusted Gross Margin Widens to 48.4%; Raises FY Growth Guidance

Bulletin Express
·
Yesterday

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Yesterday

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live
·
Yesterday

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Reuters
·
Yesterday

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Stock News
·
Yesterday

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

Reuters
·
Yesterday

WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million

THOMSON REUTERS
·
Yesterday

Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong

Dow Jones
·
Yesterday

HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results

Reuters
·
Yesterday

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Stock News
·
Yesterday

Movement Alert|WUXI BIO Rises 3.81% in Regular Trading, Interim Results Review Coincides with CXO Sector Broad Rally

Market Focus
·
Yesterday

Transcenta Holding Announces Extraordinary General Meeting

Reuters
·
Yesterday

Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition

Reuters
·
Aug 24

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Reuters
·
Aug 24

Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong

Dow Jones
·
Aug 24